Please login to the form below

Not currently logged in
Email:
Password:

Draft NICE guidance rejects GSK's Revolade

Draft guidance from the UK's NICE has not recommended GSK's Revolade for chronic immune thrombocytopenic purpura

Draft guidance from the UK's National Institute for Health and Clinical Excellence (NICE) has not recommended GlaxoSmithKline's (GSK) Revolade (eltrombopag) as a second-line treatment for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in adult patients following spleen removal.

The guidance also states the drug is not recommended for adults as a second-line treatment for the condition when surgery to remove the spleen is not advised.

Chronic ITP is a condition which causes a decrease in a patient's blood platelet production. This can lead to bruising and excessive bleeding.

Revolade is developed to increase platelet production by activating the thrombopoietin receptor, helping to reduce symptoms of chronic ITP.

Despite evidence that Revolade was effective in increasing platelet levels, the NICE Appraisal Committee who made the recommendation said that the long term effectiveness of the drug in the treatment of the condition was unclear.

The Committee also had concerns over the price of the drug, with the annual cost of treating a patient being between £22,020 and £33,030.

Speaking on the guidance, Dr Carole Longson, Health Technology Evaluation Centre director at NICE said: "From the clinical evidence presented, it is not clear how much long term health benefit eltrombopag provides, compared with current alternative treatments available. Given this and the high cost of eltrombopag in relation to the estimated health benefits the committee concluded that it could not recommend eltrombopag for people with chronic ITP."

Final NICE guidance is due to be published in October 2010.

14th September 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics